Thomas Ramdahl

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.

Omegatri AS develops tablets and powders containing Omega-3 for the health and food industry. Its products include unique administration from for omega-3, no reflux, high oxidative stability, proven bioavailability, IP protected formulation, no gelation and no lactose. The company was founded by Jo Erik Johnsrud Klaveness and Pal Rongved in 2007 and is headquartered in Oslo, Norway.

Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway.

Bayer AS trades pharmaceutical products. It also provides animal health, crop science, and consumer health. The company was founded in 1964 and is headquartered in Lysaker, Norway.

Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.

Appsens AS is a Norwegian company that develops, produces, and distributes the heart sensor ECG247. The company is based in Lillesand, Norway. The technology behind ECG247 is the result of many years of research in technology and has extensive clinical documentation of usability and accuracy. The company's technology consists of advanced algorithms, cloud-based data processing, and the use of artificial intelligence. The company was founded in 2017, and the CEO is Tord Ytterdahl.

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.